SG Americas Securities LLC Has $22.33 Million Holdings in Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• SG Americas Securities LLC boosted its stake in Kiniksa by 288.6%, buying an additional 402,078 shares to hold 541,396 shares valued at about $22.33 million (≈0.71% of the company).
• Company insiders have been net sellers — CFO Mark Ragosa sold 17,845 shares and Director Barry D. Quart sold 12,528 shares; insiders sold 48,605 shares (~$2.12M) in the past 90 days, though insiders still own 53.48% of the stock.
• Kiniksa reported Q4 EPS of $0.17 (missed estimates of $0.29) with revenue of $202.13M (up 65% YoY); the stock has a market cap of $3.58B, a P/E of 63.2, and a consensus "Moderate Buy" price target of $55.29.

SG Americas Securities LLC lifted its holdings in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 288.6% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 541,396 shares of the company's stock after purchasing an additional 402,078 shares during the period. SG Americas Securities LLC owned 0.71% of Kiniksa Pharmaceuticals International worth $22,333,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. EverSource Wealth Advisors LLC raised its position in Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company's stock worth $25,000 after purchasing an additional 532 shares during the last quarter. Osaic Holdings Inc. bought a new position in Kiniksa Pharmaceuticals International in the 2nd quarter valued at $31,000. USA Financial Formulas acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 3rd quarter valued at $32,000. Quantbot Technologies LP acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter valued at $43,000. Finally, Quarry LP bought a new stake in shares of Kiniksa Pharmaceuticals International during the third quarter worth $44,000. Institutional investors and hedge funds own 53.95% of the company's stock.

Insider Transactions at Kiniksa Pharmaceuticals International

In other news, CFO Mark Ragosa sold 17,845 shares of the company's stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $43.28, for a total value of $772,331.60. Following the completion of the sale, the chief financial officer directly owned 12,086 shares of the company's stock, valued at $523,082.08. This represents a 59.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Barry D. Quart sold 12,528 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $45.27, for a total transaction of $567,142.56. Following the completion of the sale, the director owned 12,546 shares in the company, valued at $567,957.42. This represents a 49.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 48,605 shares of company stock worth $2,122,646. Company insiders own 53.48% of the company's stock.

Kiniksa Pharmaceuticals International Stock Up 2.1%

KNSA stock opened at $46.78 on Friday. Kiniksa Pharmaceuticals International, plc has a twelve month low of $18.25 and a twelve month high of $49.12. The company has a market cap of $3.58 billion, a P/E ratio of 63.22 and a beta of 0.06. The business's fifty day moving average is $44.75 and its 200-day moving average is $41.40.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings data on Tuesday, February 24th. The company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.29 by ($0.12). The company had revenue of $202.13 million for the quarter, compared to analyst estimates of $200.86 million. Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.The firm's revenue for the quarter was up 65.0% on a year-over-year basis. During the same period last year, the firm earned ($0.12) earnings per share. Research analysts anticipate that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Wall Street Zen lowered Kiniksa Pharmaceuticals International from a "buy" rating to a "hold" rating in a research note on Saturday, March 14th. Wedbush boosted their price objective on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the stock an "outperform" rating in a report on Wednesday, February 25th. Zacks Research upgraded shares of Kiniksa Pharmaceuticals International from a "strong sell" rating to a "hold" rating in a research report on Wednesday, February 25th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, January 22nd. Finally, Canaccord Genuity Group started coverage on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, February 19th. They set a "buy" rating and a $62.00 price target for the company. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $55.29.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company's core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company's lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still's disease and Schnitzler syndrome.

Want to see what other hedge funds are holding KNSA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.